DelveInsight’s Chronic Myeloid Leukemia Pipeline Insight 2023 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Chronic Myeloid Leukemia pipeline domain. 

 

To know more about Chronic Myeloid Leukemia Pipeline report, click here: Chronic Myeloid Leukemia Pipeline Assessment

 

Some of the essential takeaways from the Chronic Myeloid Leukemia Pipeline report:

• Some of the key Chronic Myeloid Leukemia companies proactively working to develop potential drug candidates to improve the Chronic Myeloid Leukemia treatment options include Kartos Therapeutics, AOP Orphan Pharmaceuticals, BioLineRx, Incyte Corporation, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company, Enliven Therapeutics, Inhibikase Therapeutics, Kiadis Pharma, MacroGenics, Xencor, In8bio Inc, Amgen, Orca Biosystems, Inc., Gamida Cell Ltd, iCell Gene Therapeutics, Fate Therapeutics, Nohla Therapeutics, Inc.,  Takeda,  Ascentage Pharma, Xspray Pharma, Sana Biotechnology, Terns Pharmaceuticals, ImmunoForge, and many others.
• Essential Chronic Myeloid Leukemia pipeline therapies such as Navtemadlin (KRT-232), Ropeginterferon alfa 2b (BESREMi), Motixafortide, Ruxolitinib, Vodobatinib, IkT 001Pro, ELVN-001, KDS-1001, MGD024, EAGD T-cell infusion, XmAb 14045, HQP1351, KF-1601,  and others are under development in different phases of clinical trials.
• Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor which is being developed by Kartos Therapeutics. Currently, the drug is undergoing an Open-Label, Multicenter, Phase I/II Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML).
• In December 2021 Sun Pharma Advanced Research Company (SPARC) announced that an abstract on the clinical data of vodobatinib will be presented at 63rd ASH annual meeting. The majority of the Chronic Myeloid Leukemia patients enrolled in the Phase I study had failed ≥3 TKIs. Similar anti-leukemic activity (major cytogenetic response ≥60%) was observed in CML-CP patients with or without prior ponatinib treatment. The current abstract provided longer-term safety and efficacy updates to vodobatinib therapy. Vodobatinib has been granted Orphan Drug Designation for Chronic Myeloid treatment by the US Food and Drug Administration and the European Medicine Agency. 
• GDA-301 is an investigational genetically modified NAM-NK cell therapy candidate aimed at targeting hematologic malignancies and solid tumors being developed by Gamida Cell.

 

Request a sample and discover more about the report offerings @ Chronic Myeloid Leukemia Emerging Therapies

 

Chronic Myeloid Leukemia Overview

Chronic Myeloid Leukemia (CML) is a type of cancer that affects the white blood cells and tends to progress slowly over many years. It can occur at any age but is most common in older adults around 60-65 years of age. In Chronic Myeloid Leukemia, the spongy material inside some bones (bone marrow) produces too many myeloid cells – immature white blood cells that are not fully developed and do not work properly. Chronic Myeloid Leukemia signs and symptoms does not usually appear in early stages.

 

Chronic Myeloid Leukemia Pipeline Therapeutics Assessment

The Chronic Myeloid Leukemia Pipeline report proffers an integral view of the Chronic Myeloid Leukemia emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.

 

Scope of the Chronic Myeloid Leukemia Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Chronic Myeloid Leukemia Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Chronic Myeloid Leukemia Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
• Therapeutics Assessment By Chronic Myeloid Leukemia Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Chronic Myeloid Leukemia Molecule Type: Small molecules, Oligonucleotide, Peptide
• Therapeutics Assessment By Chronic Myeloid Leukemia Mechanism of Action: Bcr-abl tyrosine kinase inhibitors; CXCR4 receptor antagonists; Janus kinase 1 inhibitor; Janus kinase-2 inhibitor; Interferon alpha-2 replacement, Phosphotransferase inhibitor, and Proto-oncogene protein c mdm2 inhibitor, Antibody-dependent cell cytotoxicity; T lymphocyte stimulant. 
• Key Chronic Myeloid Leukemia Companies: Kartos Therapeutics, AOP Orphan Pharmaceuticals, BioLineRx, Incyte Corporation, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company, Enliven Therapeutics, Inhibikase Therapeutics, Kiadis Pharma, MacroGenics, Xencor, In8bio Inc, Amgen, Orca Biosystems, Inc., Gamida Cell Ltd, iCell Gene Therapeutics, Fate Therapeutics, Nohla Therapeutics, Inc.,  Takeda,  Ascentage Pharma, Xspray Pharma, Sana Biotechnology, Terns Pharmaceuticals, ImmunoForge, and many others.
• Key Chronic Myeloid Leukemia Pipeline Therapies:  Navtemadlin (KRT-232), Ropeginterferon alfa 2b (BESREMi), Motixafortide, Ruxolitinib, Vodobatinib, IkT 001Pro, ELVN-001, KDS-1001, MGD024, EAGD T-cell infusion, XmAb 14045, HQP1351, KF-1601, and others are under development in different phases of clinical trials.

 

Dive deep into rich insights for emerging therapies and assessment, visit @ Chronic Myeloid Leukemia Pipeline and Emerging Therapies

 

Table of Contents 

1	Introduction
2	Executive Summary
3	Chronic Myeloid Leukemia Overview
4	Chronic Myeloid Leukemia Pipeline Therapeutics
5	Late Stage Products (Phase III)
5.1	Ropeginterferon alfa 2b: AOP Orphan Pharmaceutical
6	Mid Stage Products (Phase II)
6.1	Ruxolitinib: Incyte Corporation/Novartis
7	Early Stage Products (Phase I)
7.1	MGD 024: MacroGenics
8	Preclinical and Discovery Stage Products
8.1	IkT 001Pro: Inhibikase Therapeutics
9	Inactive Chronic Myeloid Leukemia Products
10	Collaborations Assessment- Licensing / Partnering / Funding
11	Chronic Myeloid Leukemia Unmet Needs
12	Chronic Myeloid Leukemia Market Drivers and Barriers
13	Appendix
14	About DelveInsight

 

For further information on the current Chronic Myeloid Leukemia pipeline therapeutics, reach out @ Chronic Myeloid Leukemia Ongoing Clinical Trials

 

Trending Reports:

Pediatric Growth Hormone Deficiency Market

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting